Values of the " IP " for the various Diseases from the 2015 Commercial Valuation of Pharmaust ASX ;PAA
In 2015 the Cancer IP and Epichem had a High Valuation of $98,918,000
The Value of actual Treatments are 10 times the IP Valuation and they are from 2015 so add 7 years of inflation etcActual Valuation https://pharmaust.com/wp-content/uploads/2017/11/150908_Actuity_-PHARMAUST-valuation-08-09-15signed.pdfCertainly great value 7 years later with Empirical Evidence of MPL's actual ability to reduce all of the above cancer cell lines..NZT
MONEPANTEL - A Pan-Cancer Wonder Drug, page-55
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $99.71M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $66.86K | 327.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27750 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 84999 | 3 |
View Market Depth
| Last trade - 14.42pm 27/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |